TAGUNGSMAPPE
|
Die Veranstaltung umfasst folgende Beiträge:
|
Nr. |
Thema |
Kurzf. |
Folien |
11459
| FDA´s and USP´s Role in the analytical and regulatory area | - | 47 |
11460
| FDA Inspections in Pharmaceutical Quality Control Laboratories | - | 37 |
11461
| FDA Inspections of Electronic Record Integrity | - | 29 |
11462
| Continuing FDA Inspection Attention: OOS and Failure Investifation | - | 42 |
11463
| International Pharmacopoeial Harmonisation | - | 32 |
11464
| Trust but Verify; USP Good Practices for the Quality Assurance of analytical Instrumentation | - | 39 |
11465
| Control of Impurities in Drug Substances abd Products for Pharmaceutical Use | - | 53 |
11466
| Residual Solvents Determination According to USP General Chapter <467> and FDA Expectations | - | 34 |
11467
| Heavy Metals - REvision of USP Gerenal Chapter <231> | - | - |
11468
| USP Reference Standards | - | 34 |
11469
| How to Deal with Divergent Compendial Method Requirements (EP,JP) and to comply with USP/FDA | - | 20 |
11470
| Validation of (Compendial) Methods - Introduction of ISO Terminology in the Pharmaceutical World | - | 37 |
11471
| Chromatography and System Suitability in USP Gerenal Chapter <621> - Common and Different Approaches to Ph. Eur. Chapter 2.2.46 | - | 38 |
11472
| Quality of Calibrate? The USP versus the FDA on Qualification of Dissolution Baths | - | 34 |
|
